Vividion Announces Publication of Clinical Data for VVD-214 in Nature Medicine, Highlighting Potential in Colorectal Cancer

SAN DIEGO–(BUSINESS WIRE)–Vividion announces publication of first peer-reviewed clinical data from Phase 1 study of VVD-214, investigational oral inhibitor of WRN.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.